For the Inventor, By the Inventor

Enter assignee name

Redwood City, CA, United States of America

Abbvie Biotherapeutics Inc.

USPTO Granted Patents = 51

CIPO Patents = 9

EPO Patents = 23

Forward Citations = 273

Loading Chart...

Loading Chart...

50 inventors (with patents filed for the assignee):

J Yun Tso (10 out of 48 patents)

Yoshiko Akamatsu (10 out of 10 patents)

David Powers (10 out of 24 patents)

4. Fiona A Harding (10 out of 26 patents)

5. Robert B Dubridge (9 out of 47 patents)

6. Kurt C Gish (7 out of 27 patents)

7. Shiming Ye (6 out of 6 patents)

8. Marna Williams (6 out of 11 patents)

9. Nicholas F Landolfi (6 out of 19 patents)

10. Gao Liu (6 out of 13 patents)

11. Diane Sau Mun Cohen (5 out of 5 patents)

12. Diane Hollenbaugh (5 out of 20 patents)

13. Ping Y Huang (5 out of 6 patents)

14. Veronica Juan (4 out of 15 patents)

15. James W Purcell (4 out of 4 patents)

Core Competencies:

Anti-CD19 Antibody Drug Conjugates

Anti-huLRRC15 Antibody Drug Conjugates

Anti-4-1BB Antibodies

Anti-PD-1 Antibodies

Bispecific Binding Proteins

Fc Variants

Anti-VEGF Antibodies

CTLA4 Proteins

Anti-TNF-alpha Antibodies

Nucleic Acid Molecules

Therapeutic Use of Anti-CS1 Antibodies

Stable Aqueous Pharmaceutical Formulations

51 patents: Sort by Forward Citations

1. 12121589 - Anti-CD19 antibody drug conjugates (2024-10-22),

2. 11045480 - Anti-huLRRC15 antibody drug conjugates and methods for their use (2021-06-29),

3. 10875921 - Anti-4-1BB antibodies and their uses (2020-12-29),

4. 10844131 - Anti-CD40 antibody (2020-11-24),

5. 10730953 - Anti-PD-1 antibodies and their uses (2020-08-04),

6. 10604584 - Anti-OX40 antibodies and their uses (2020-03-31),

7. 10603389 - Anti-cMet antibody drug conjugates and methods for their use (2020-03-31),

8. 10597460 - Anti-CD40 antibodies (2020-03-24),

9. 10556962 - Anti-OX40 antibodies and their uses (2020-02-11),

10. 10519243 - Anti-CD40 antibodies (2019-12-31),

11. 10442859 - Therapeutic use of anti-CS1 antibodies (2019-10-15),

12. 10400041 - Nucleic acid molecules encoding anti-CD40 antibodies (2019-09-03),

13. 10383948 - Anti-cMet antibody drug conjugates and methods for their use (2019-08-20),

14. 10308713 - Anti-CS1 antibodies and antibody drug conjugates (2019-06-04),

15. 10233258 - Bispecific binding proteins that bind CD40 and mesothelin (2019-03-19),

AbbVie Biotherapeutics Inc. is a biopharmaceutical company dedicated to discovering and developing innovative therapies to address serious health conditions. With a rigorous research and development approach, AbbVie Biotherapeutics aims to tackle some of the world's most pressing medical challenges. They focus on a wide range of therapeutic areas, including immunology, oncology, neuroscience, and virology. Through their commitment to scientific excellence and patient-centered solutions, AbbVie Biotherapeutics is striving to improve lives around the globe.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 30 2025

51 Patents

#38 in Redwood City, CA

#1,580 in California

#6,661 in US

#13,382 in the World

Redwood City, CA, United States of America

Abbvie Biotherapeutics Inc.

Forward Citations = 273

50 inventors:

J Yun Tso (10 out of 48 patents)

Yoshiko Akamatsu (10 out of 10 patents)

David Powers (10 out of 24 patents)

4. Fiona A Harding (10 out of 26 patents)

5. Robert B Dubridge (9 out of 47 patents)

Please report any incorrect information to support@idiyas.com

Loading…